[{"id":"d5afe40d-858e-4e8c-a552-782c25a7e99d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06834529","created_at":"2025-02-25T14:05:59.231Z","updated_at":"2025-02-25T14:05:59.231Z","phase":"Phase 1/2","brief_title":"CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma","source_id_and_acronym":"NCT06834529","lead_sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 01/20/2025","start_date":" 01/20/2025","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2025-02-19"},{"id":"cf53eb98-b376-49ff-89cf-7b0f098f93c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06343090","created_at":"2024-04-02T20:42:22.091Z","updated_at":"2025-02-25T15:28:51.099Z","phase":"","brief_title":"Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients","source_id_and_acronym":"NCT06343090","lead_sponsor":"Beijing GoBroad Hospital","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"],"overall_status":"Recruiting","enrollment":" Enrollment 353","initiation":"Initiation: 04/12/2024","start_date":" 04/12/2024","primary_txt":" Primary completion: 12/01/2042","primary_completion_date":" 12/01/2042","study_txt":" Completion: 09/30/2043","study_completion_date":" 09/30/2043","last_update_posted":"2025-02-11"},{"id":"ad314edd-2963-47ac-86cd-5f06a81ee36e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06005649","created_at":"2023-08-22T15:08:54.438Z","updated_at":"2025-02-25T16:33:37.494Z","phase":"Phase 1/2","brief_title":"Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT06005649","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" BCL2 • BCL6 • IL6 • CD22","pipe":" | ","alterations":" CD19 positive","tags":["BCL2 • BCL6 • IL6 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • HY004"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-07"},{"id":"d7d0a6de-b0e3-4648-b4e9-ec298fd54104","acronym":"B-ALL","url":"https://clinicaltrials.gov/study/NCT06009107","created_at":"2024-03-13T08:35:11.520Z","updated_at":"2025-02-25T16:33:38.314Z","phase":"Phase 1/2","brief_title":"A Study of HY004 Treatment in Adult Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)","source_id_and_acronym":"NCT06009107 - B-ALL","lead_sponsor":"Juventas Cell Therapy Ltd.","biomarkers":" IL6","pipe":" | ","alterations":" CD19 expression","tags":["IL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • HY004"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 12/30/2026","primary_completion_date":" 12/30/2026","study_txt":" Completion: 12/30/2027","study_completion_date":" 12/30/2027","last_update_posted":"2025-02-07"},{"id":"5721b478-7256-41e9-bdb4-f8b5fa921a9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05418088","created_at":"2022-06-14T21:56:15.500Z","updated_at":"2025-02-25T17:01:57.164Z","phase":"Phase 1","brief_title":"Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies","source_id_and_acronym":"NCT05418088","lead_sponsor":"Sumithira Vasu","biomarkers":" CD20 • CD19 • CD22","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TriCAR19.20.22 T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2025-02-03"},{"id":"ec81dee1-ccab-428c-9718-7a66b69c4ece","acronym":"","url":"https://clinicaltrials.gov/study/NCT06743503","created_at":"2025-02-26T07:40:37.187Z","updated_at":"2025-02-26T07:40:37.187Z","phase":"Phase 1","brief_title":"UB-VV400 in Combination with Rapamycin in Relapsed or Refractory B-cell Malignancies","source_id_and_acronym":"NCT06743503","lead_sponsor":"Nanjing IASO Biotechnology Co., Ltd.","biomarkers":" CD20 • CD8 • CD4 • NCAM1 • FOXP3","pipe":"","alterations":" ","tags":["CD20 • CD8 • CD4 • NCAM1 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sirolimus"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 12/31/2024","start_date":" 12/31/2024","primary_txt":" Primary completion: 05/21/2028","primary_completion_date":" 05/21/2028","study_txt":" Completion: 07/31/2030","study_completion_date":" 07/31/2030","last_update_posted":"2024-12-20"},{"id":"3a35ee83-442b-425a-b135-8f3ccbaaf11f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06559189","created_at":"2025-02-27T08:09:32.925Z","updated_at":"2025-02-27T08:09:32.925Z","phase":"Phase 1","brief_title":"CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL","source_id_and_acronym":"NCT06559189","lead_sponsor":"University of Colorado, Denver","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19x22 CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 09/27/2024","start_date":" 09/27/2024","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2024-10-18"},{"id":"4b1e2885-ae3f-433a-8a0a-828ebea2022b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03448393","created_at":"2021-01-18T17:00:10.946Z","updated_at":"2024-07-02T16:34:37.765Z","phase":"Phase 1","brief_title":"CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies","source_id_and_acronym":"NCT03448393","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD19 expression • CD22 expression","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 03/26/2018","start_date":" 03/26/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/31/2040","study_completion_date":" 12/31/2040","last_update_posted":"2024-06-06"},{"id":"1c9f6138-8d9a-47fc-a239-63c21b0bb4fc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04815356","created_at":"2021-03-25T12:52:31.393Z","updated_at":"2024-07-02T16:34:38.088Z","phase":"Phase 1","brief_title":"Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant","source_id_and_acronym":"NCT04815356","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • JCAR018 • anti-CD22 CAR T"],"overall_status":"Recruiting","enrollment":" Enrollment 27","initiation":"Initiation: 05/23/2022","start_date":" 05/23/2022","primary_txt":" Primary completion: 12/01/2036","primary_completion_date":" 12/01/2036","study_txt":" Completion: 12/01/2036","study_completion_date":" 12/01/2036","last_update_posted":"2024-06-05"},{"id":"dab15a96-876b-4fdc-b04d-c6d8c5e516df","acronym":"","url":"https://clinicaltrials.gov/study/NCT02315612","created_at":"2021-01-18T10:58:15.939Z","updated_at":"2024-07-02T16:34:58.824Z","phase":"Phase 1","brief_title":"Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies","source_id_and_acronym":"NCT02315612","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JCAR018 • anti-CD22 CAR T"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 12/12/2014","start_date":" 12/12/2014","primary_txt":" Primary completion: 04/03/2019","primary_completion_date":" 04/03/2019","study_txt":" Completion: 06/01/2040","study_completion_date":" 06/01/2040","last_update_posted":"2024-06-05"},{"id":"14b28ae8-831d-4306-9aa4-5c102afbfa3f","acronym":"CARPALL","url":"https://clinicaltrials.gov/study/NCT02443831","created_at":"2021-01-18T11:42:34.871Z","updated_at":"2024-07-02T16:35:00.037Z","phase":"Phase 1","brief_title":"CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies","source_id_and_acronym":"NCT02443831 - CARPALL","lead_sponsor":"University College, London","biomarkers":" ABL1 • BCR • KMT2A • IGH • CD22 • TCF3","pipe":" | ","alterations":" KMT2A rearrangement • MLL rearrangement","tags":["ABL1 • BCR • KMT2A • IGH • CD22 • TCF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KMT2A rearrangement • MLL rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • AUTO1/22 • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 12/31/2036","study_completion_date":" 12/31/2036","last_update_posted":"2024-05-30"},{"id":"ee6449ac-5095-4fbb-b724-e910caded562","acronym":"","url":"https://clinicaltrials.gov/study/NCT03620058","created_at":"2021-01-18T17:47:19.570Z","updated_at":"2024-07-02T16:35:00.949Z","phase":"Phase 1","brief_title":"CART22 Alone or in Combination With huCART19 for ALL","source_id_and_acronym":"NCT03620058","lead_sponsor":"University of Pennsylvania","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CART22 • huCART19"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 09/27/2018","start_date":" 09/27/2018","primary_txt":" Primary completion: 01/01/2036","primary_completion_date":" 01/01/2036","study_txt":" Completion: 01/01/2036","study_completion_date":" 01/01/2036","last_update_posted":"2024-05-24"},{"id":"475a7d05-25ee-4633-ae5e-c6600c4536e9","acronym":"","url":"https://clinicaltrials.gov/study/NCT06408194","created_at":"2024-05-11T04:17:51.062Z","updated_at":"2024-07-02T16:35:01.945Z","phase":"Phase 1","brief_title":"Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies","source_id_and_acronym":"NCT06408194","lead_sponsor":"Stanford University","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kymriah (tisagenlecleucel-T) • firicabtagene autoleucel (CRG-022)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/13/2024","start_date":" 05/13/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-05-22"},{"id":"41b868a7-e7be-446b-8235-fde40165cb18","acronym":"","url":"https://clinicaltrials.gov/study/NCT05292898","created_at":"2022-03-23T13:53:39.110Z","updated_at":"2024-07-02T16:35:03.931Z","phase":"Phase 1","brief_title":"A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia","source_id_and_acronym":"NCT05292898","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" CD20 • CD22","pipe":" | ","alterations":" CD19 expression","tags":["CD20 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • LCAR-AIO"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/14/2022","start_date":" 03/14/2022","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-05-14"},{"id":"aae6f5f0-c07c-406a-9440-452713bc328a","acronym":"BAH241","url":"https://clinicaltrials.gov/study/NCT06213636","created_at":"2024-01-19T17:20:48.484Z","updated_at":"2024-07-02T16:35:10.842Z","phase":"Phase 1/2","brief_title":"Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).","source_id_and_acronym":"NCT06213636 - BAH241","lead_sponsor":"Essen Biotech","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 11/10/2024","start_date":" 11/10/2024","primary_txt":" Primary completion: 02/10/2025","primary_completion_date":" 02/10/2025","study_txt":" Completion: 12/10/2025","study_completion_date":" 12/10/2025","last_update_posted":"2024-04-09"},{"id":"b57a2c09-5314-4526-80dc-a9991f983474","acronym":"","url":"https://clinicaltrials.gov/study/NCT04571138","created_at":"2021-01-18T21:49:43.303Z","updated_at":"2024-07-02T16:35:10.673Z","phase":"Phase 1/2","brief_title":"A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma","source_id_and_acronym":"NCT04571138","lead_sponsor":"Seattle Children's Hospital","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SCRI-CAR22v2"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 09/25/2020","start_date":" 09/25/2020","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 02/01/2040","study_completion_date":" 02/01/2040","last_update_posted":"2024-04-09"},{"id":"4597a802-a7f3-4236-8973-beeba9195822","acronym":"","url":"https://clinicaltrials.gov/study/NCT06208735","created_at":"2024-01-17T21:20:13.123Z","updated_at":"2024-07-02T16:35:11.114Z","phase":"Phase 1","brief_title":"CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies","source_id_and_acronym":"NCT06208735","lead_sponsor":"British Columbia Cancer Agency","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 07/01/2024","start_date":" 07/01/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-04-05"},{"id":"015bee1f-dfaa-4768-9837-b466448d181f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06340737","created_at":"2024-04-01T19:42:38.783Z","updated_at":"2024-07-02T16:35:11.716Z","phase":"Phase 1","brief_title":"AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas","source_id_and_acronym":"NCT06340737","lead_sponsor":"Stanford University","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 03/29/2024","start_date":" 03/29/2024","primary_txt":" Primary completion: 04/01/2031","primary_completion_date":" 04/01/2031","study_txt":" Completion: 04/01/2031","study_completion_date":" 04/01/2031","last_update_posted":"2024-04-03"},{"id":"d0063cdd-ab4b-4009-8105-73c4b7241cf5","acronym":"IRB-50836","url":"https://clinicaltrials.gov/study/NCT04088890","created_at":"2021-01-18T20:00:46.615Z","updated_at":"2024-07-02T16:35:15.877Z","phase":"Phase 1","brief_title":"Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies","source_id_and_acronym":"NCT04088890 - IRB-50836","lead_sponsor":"Stanford University","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive • CD22 expression • CD20 negative","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD22 expression • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • firicabtagene autoleucel (CRG-022)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 09/12/2019","start_date":" 09/12/2019","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2037","study_completion_date":" 12/30/2037","last_update_posted":"2024-03-07"},{"id":"a9929cf7-40a1-4942-a4c2-1a9b6e8d511b","acronym":"NatHaLi-01","url":"https://clinicaltrials.gov/study/NCT05607420","created_at":"2022-11-07T13:56:26.754Z","updated_at":"2024-07-02T16:35:16.800Z","phase":"Phase 1/2","brief_title":"Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05607420 - NatHaLi-01","lead_sponsor":"Cellectis S.A.","biomarkers":" BCL2 • BCL6 • CD22","pipe":" | ","alterations":" CD20 positive • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Campath (alemtuzumab) • etivelcabtagene erigedleucel (UCART20x22)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-03-01"},{"id":"b244d21b-7ca6-459d-808a-603983ee64ea","acronym":"","url":"https://clinicaltrials.gov/study/NCT03233854","created_at":"2021-01-18T15:58:49.473Z","updated_at":"2024-07-02T16:35:17.505Z","phase":"Phase 1","brief_title":"CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies","source_id_and_acronym":"NCT03233854","lead_sponsor":"Crystal Mackall, MD","biomarkers":" CD19 • CD22","pipe":" | ","alterations":" CD19 positive • CD19 expression • CD22 expression","tags":["CD19 • CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • CD19 expression • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • avipendekin pegol (NKTR-255) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 09/01/2017","start_date":" 09/01/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2035","study_completion_date":" 09/01/2035","last_update_posted":"2024-02-28"},{"id":"b2fd0720-c684-4f4d-8475-75c34a4514c6","acronym":"","url":"https://clinicaltrials.gov/study/NCT04088864","created_at":"2021-01-18T20:00:46.042Z","updated_at":"2024-07-02T16:35:19.768Z","phase":"Phase 1","brief_title":"CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies","source_id_and_acronym":"NCT04088864","lead_sponsor":"Stanford University","biomarkers":" CD22","pipe":" | ","alterations":" CD22 positive • CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 positive • CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous • firicabtagene autoleucel (CRG-022)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 01/10/2020","start_date":" 01/10/2020","primary_txt":" Primary completion: 10/31/2023","primary_completion_date":" 10/31/2023","study_txt":" Completion: 09/10/2036","study_completion_date":" 09/10/2036","last_update_posted":"2024-02-12"},{"id":"333c3c91-e311-42ae-a48a-8af632ca1e7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02650414","created_at":"2021-01-18T12:54:06.464Z","updated_at":"2024-07-02T16:35:20.907Z","phase":"Phase 1","brief_title":"CD22 Redirected Autologous T Cells for ALL","source_id_and_acronym":"NCT02650414","lead_sponsor":"University of Pennsylvania","biomarkers":" CD22","pipe":" | ","alterations":" CD22 expression","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD22 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CART22"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/13/2016","start_date":" 01/13/2016","primary_txt":" Primary completion: 12/01/2037","primary_completion_date":" 12/01/2037","study_txt":" Completion: 12/01/2037","study_completion_date":" 12/01/2037","last_update_posted":"2024-02-05"},{"id":"8b4b85ac-4eb7-4ae3-8f3d-9a949ba6aaaa","acronym":"ALEXANDER","url":"https://clinicaltrials.gov/study/NCT03287817","created_at":"2021-01-18T16:14:33.110Z","updated_at":"2024-07-02T16:35:24.309Z","phase":"Phase 1/2","brief_title":"CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT03287817 - ALEXANDER","lead_sponsor":"Autolus Limited","biomarkers":" MYC • BCL2 • BCL6","pipe":" | ","alterations":" MYC expression • BCL6 rearrangement • BCL2 rearrangement • CD20 negative","tags":["MYC • BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression • BCL6 rearrangement • BCL2 rearrangement • CD20 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • AUTO3"],"overall_status":"Completed","enrollment":" Enrollment 73","initiation":"Initiation: 09/05/2017","start_date":" 09/05/2017","primary_txt":" Primary completion: 12/06/2023","primary_completion_date":" 12/06/2023","study_txt":" Completion: 12/06/2023","study_completion_date":" 12/06/2023","last_update_posted":"2024-01-08"}]